NYSE:PFE Earnings and Revenue History November 11th 2025 How Do Unusual Items Influence Profit? To properly understand Pfizer ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Investing.com -- Metsera Inc. (NASDAQ:MTSR) stock tumbled as much as 16% to $70.15 in premarket trading Monday after Novo Nordisk A/S (NYSE:NVO) abandoned its pursuit of the US weight-loss drug ...

One struggling pharma stock that could use a boost from a strong earnings report is Pfizer (NYSE: PFE). The company's valuation has plummeted in recent years as patent cliffs and ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...